<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methdilazine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00902</strong>&#160; (APRD00713)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00902/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00902/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00902.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00902.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00902.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00902.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00902.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00902">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Methdilazinum</td><td>Latin</td><td>INN</td></tr><tr><td>Metodilazina</td><td>Spanish</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Methdilazine Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000486/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000486/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: IEISBKIVLDXSMZ-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 332.111397079</li>
              <li>Average Mass: 332.891</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000486">DBSALT000486</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Dilosyn</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tacaryl</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/histamine-antagonists">Histamine Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>1982-37-2</td></tr><tr><th>Weight</th><td>Average: 296.43<br>Monoisotopic: 296.13471934</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>HTMIBDQKFHUPSX-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00902.gif?1265922772">show</a>(11 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzothiazines</td></tr><tr><th>Subclass</th><td>Phenothiazines</td></tr><tr><th>Direct parent</th><td>Phenothiazines</td></tr><tr><th>Alternative parents</th><td>Benzene and Substituted Derivatives; Pyrrolidines; Tertiary Amines; Polyamines; Thioethers</td></tr><tr><th>Substituents</th><td>benzene; pyrrolidine; tertiary amine; polyamine; thioether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders</td></tr><tr><th>Pharmacodynamics</th><td>In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H<sub>1</sub>-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Methdilazine is a histamine H<sub>1</sub> antagonist. It competes with histamine for the normal H<sub>1</sub>-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.</td></tr><tr><th>Mechanism of action</th><td>Methdilazine binds to the histamine H<sub>1</sub> receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.</td></tr><tr><th>Absorption</th><td>Well absorbed in the digestive tract.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include clumsiness or unsteadiness, convulsions, drowsiness, dryness of mouth, nose, or throat, feeling faint, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath or troubled breathing, shuffling walk, tic-like movements of head and face, trembling and shaking of hands, and trouble in sleeping.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9901</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9949</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7779</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7768</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.605</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.864</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.834</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7288</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.7763</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.526</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9072</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.9056</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9346</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6238</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9678
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9972
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.2306 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8634
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7305
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Westwood squibb pharmaceuticals inc</li>
<li>Alpharma us pharmaceuticals division</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00937">Diethylpropion</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Methdilazine may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB00579">Mazindol</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>